Mark E. Dmytruk - 01 Mar 2023 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role: Chief Financial Officer
Signature: /s/ Karen Tepichin, Attorney-in-Fact
Issuer symbol: DNA
Transactions as of: 01 Mar 2023
Net transactions value: $0
Form type: 4
Filing time: 03 Mar 2023, 16:30:09 UTC
Previous filing: 03 Feb 2023
Next filing: 16 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DNA	Class A Common Stock	Options Exercise		+1,635	+0.33%		495,217	01 Mar 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DNA	Class B Common Stock	Options Exercise		-1,635	-0.25%		649,953	01 Mar 2023	Class A Common Stock	1,635		Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.
F2	Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.
F3	Includes shares of Class B Common Stock that are subject to vesting conditions.

Remarks:

Chief Financial Officer